Chapin Davis Inc. bought a new position in Xylem Inc. (NYSE:XYL – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,645 shares of the industrial products company’s stock, valued at approximately $213,000.
Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Xylem by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 28,048,996 shares of the industrial products company’s stock valued at $3,207,683,000 after acquiring an additional 187,847 shares during the last quarter. Morgan Stanley lifted its position in Xylem by 11.5% in the 3rd quarter. Morgan Stanley now owns 4,528,905 shares of the industrial products company’s stock worth $412,267,000 after buying an additional 466,911 shares during the last quarter. Royal Bank of Canada lifted its position in Xylem by 10.6% in the 3rd quarter. Royal Bank of Canada now owns 3,408,200 shares of the industrial products company’s stock worth $310,249,000 after buying an additional 327,383 shares during the last quarter. Baillie Gifford & Co. lifted its position in Xylem by 2.3% in the 4th quarter. Baillie Gifford & Co. now owns 3,066,639 shares of the industrial products company’s stock worth $350,701,000 after buying an additional 69,619 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its position in Xylem by 0.7% in the 4th quarter. Victory Capital Management Inc. now owns 2,527,487 shares of the industrial products company’s stock worth $289,043,000 after buying an additional 16,713 shares during the last quarter. Institutional investors own 87.96% of the company’s stock.
Xylem Trading Down 3.0 %
Shares of XYL stock opened at $131.53 on Tuesday. The stock has a market capitalization of $31.89 billion, a P/E ratio of 46.81, a P/E/G ratio of 2.40 and a beta of 1.04. The company has a current ratio of 1.67, a quick ratio of 1.22 and a debt-to-equity ratio of 0.19. The firm’s 50 day moving average is $138.78 and its 200 day moving average is $127.28. Xylem Inc. has a 12-month low of $87.59 and a 12-month high of $146.08.
Xylem Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Thursday, May 30th were given a $0.36 dividend. The ex-dividend date was Thursday, May 30th. This represents a $1.44 annualized dividend and a yield of 1.09%. Xylem’s payout ratio is presently 51.25%.
Insider Transactions at Xylem
In other Xylem news, SVP Rodney Aulick sold 21,800 shares of the business’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $139.01, for a total transaction of $3,030,418.00. Following the completion of the sale, the senior vice president now owns 76,287 shares of the company’s stock, valued at $10,604,655.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CAO Geri-Michelle Mcshane sold 2,278 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $138.63, for a total value of $315,799.14. Following the transaction, the chief accounting officer now directly owns 3,536 shares in the company, valued at $490,195.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Rodney Aulick sold 21,800 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $139.01, for a total value of $3,030,418.00. Following the completion of the transaction, the senior vice president now directly owns 76,287 shares in the company, valued at $10,604,655.87. The disclosure for this sale can be found here. Corporate insiders own 0.27% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on the company. BNP Paribas assumed coverage on Xylem in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $150.00 price target on the stock. Royal Bank of Canada lifted their price target on Xylem from $157.00 to $162.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Mizuho lifted their price target on Xylem from $110.00 to $135.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. TD Cowen boosted their target price on Xylem from $135.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, June 6th. Finally, Argus lifted their price target on Xylem from $146.00 to $165.00 and gave the company a “buy” rating in a research report on Wednesday, May 29th. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $142.92.
View Our Latest Report on Xylem
Xylem Company Profile
Xylem Inc, together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions worldwide. It operates through four segments: Water Infrastructure, Applied Water, Measurement & Control Solutions, and Integrated Solutions and Services. The Water Infrastructure segment offers products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the ADI, Flygt, Godwin, Sanitaire, Magneto, Neptune Benson, Ionpure, Leopold, Wedeco, and Xylem Vue brands.
Featured Stories
- Five stocks we like better than Xylem
- How to Calculate Inflation Rate
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What Investors Need to Know to Beat the Market
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Want to see what other hedge funds are holding XYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xylem Inc. (NYSE:XYL – Free Report).
Receive News & Ratings for Xylem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xylem and related companies with MarketBeat.com's FREE daily email newsletter.